human
rhinovirus
hrv
ubiquit
pathogen
lead
caus
common
cold
syndrom
consid
mostli
nuisanc
virus
appreci
caus
medic
signific
ill
substanti
burden
diseas
although
ill
typic
mild
selflimit
lost
time
work
school
creat
consider
econom
burden
infect
upper
airway
common
site
infect
although
lower
airway
diseas
also
well
document
link
hrv
infect
exacerb
asthma
unfortun
effect
specif
antivir
treatment
vaccin
remain
elus
articl
basic
virolog
pathogenesi
diseas
epidemiolog
clinic
manifest
current
method
treatment
prevent
review
hrv
member
enteroviru
genu
within
picornavirida
famili
sinc
first
identifi
serotyp
rhinoviru
cultur
distinguish
distinct
neutral
antibodi
serotyp
classifi
two
speci
hrva
hrvb
though
recent
year
sequenc
technolog
led
identif
genotyp
virus
grow
cultur
place
third
speci
hrvc
bochkov
et
al
rhinovirus
also
classifi
basi
receptor
specif
major
receptor
group
compris
serotyp
b
use
intercellular
adhes
molecul
receptor
infect
host
cell
staunton
et
al
twelv
hrva
serotyp
use
altern
site
lowdens
lipoprotein
receptor
ldlr
receptor
hrvc
virus
human
cadherinrel
famili
member
bochkov
et
al
rhinovirus
small
nonenvelop
virus
singl
strand
positivesens
rna
greenberg
virion
compos
kb
genom
materi
pack
icosahedr
protein
shell
known
capsid
royston
tapparel
figur
capsid
turn
compris
pentam
five
protein
subunit
call
protom
contain
four
viral
protein
capsid
compris
pentam
central
share
depress
canyon
c
protom
protein
subunit
pentam
contain
four
viral
protein
protein
form
hydrophob
pocket
canyon
region
serv
bind
site
intercellular
adhes
molecul
receptor
host
cell
pentam
contain
central
share
depress
canyon
five
protein
protom
subunit
serv
bind
site
receptor
host
cell
figur
b
c
attach
host
cell
achiev
viral
replic
occur
host
cell
cytoplasm
antibodi
neutral
occur
igg
bind
viral
surfac
obstruct
access
hostcel
receptor
viral
attach
site
base
canyon
turner
also
found
surfac
capsid
antigen
site
import
host
immun
respons
locat
intern
side
capsid
interact
viral
genom
genom
data
code
somewhat
conserv
among
variou
subtyp
hrv
though
variat
account
antigen
divers
among
serotyp
imped
develop
effect
vaccin
antivir
agent
infect
occur
hrv
must
reach
nasal
mucosa
suscept
individu
transmiss
infect
suscept
individu
like
occur
viral
load
highest
secret
plenti
difficult
control
experiment
condit
viral
titer
tcid
tissu
cultur
infect
dose
need
transmit
infect
often
occur
day
cold
peak
symptom
turner
epidemiolog
evid
suggest
direct
contact
selfinocul
account
major
hrv
transmiss
classic
transmiss
studi
infect
suscept
subject
demonstr
hand
hand
hand
intermediari
surfac
recipi
selfinocul
effici
transmit
hrv
hendley
et
al
recent
experiment
studi
shown
transmiss
hrv
possibl
small
larg
particl
aerosol
frequent
occur
natur
set
unclear
viru
reach
nasal
mucosa
attach
epitheli
cell
occur
via
receptor
infect
ldlr
receptor
depend
serotyp
pitkaranta
hayden
hrv
grow
best
c
cell
cultur
primarili
upper
respiratori
tract
although
infect
lower
airway
sinus
higher
bodi
temperatur
possibl
ciliat
noncili
epitheli
cell
infect
infect
progress
affect
area
may
patchi
figur
hrv
infect
cytopath
gener
accept
major
symptom
due
host
inflammatori
respons
infect
limit
respiratori
tract
rare
report
invas
diseas
brownle
turner
although
hrv
rare
cultur
blood
hrv
rna
detect
plasma
normal
children
hrv
infect
common
sever
ill
asthma
exacerb
howev
unclear
detect
viral
rna
plasma
truli
repres
system
infect
infect
establish
complex
interplay
neurogen
host
respons
occur
earli
infect
character
vigor
inflammatori
respons
brought
elabor
varieti
proinflammatori
cytokin
chemokin
includ
interleukin
il
interferoninduc
protein
pitkaranta
hayden
turner
concentr
inflammatori
mediat
correl
sever
symptom
result
influx
neutrophil
increas
vascular
permeabl
swell
nasal
mucosa
leakag
serum
nasal
secret
kinin
bradykinin
lysyl
bradykinin
also
found
secret
hrvinfect
individu
presenc
concentr
also
correl
symptom
yet
treatment
block
kinin
ineffectu
allevi
symptom
rais
question
relev
kinin
hrv
diseas
pathogenesi
moreov
despit
frequenc
antihistamin
mani
cold
treatment
evid
histamin
releas
hrv
infect
may
due
fact
neurogen
reflex
also
appear
play
role
diseas
pathogenesi
parasympathet
nerv
control
flow
secret
nasal
seromuc
gland
final
import
hrv
infect
asthma
exacerb
well
recogn
gern
buss
precis
mechan
occur
yet
fulli
investig
appear
involv
genet
predisposit
allerg
airway
factor
measur
immunoglobulin
e
ige
hrvspecif
neutral
antibodi
shown
protect
infect
symptom
homolog
virus
gwaltney
et
al
infect
result
product
serum
igg
nasal
iga
begin
around
week
infect
result
longlast
protect
specif
infect
hrv
serotyp
resolut
symptom
clearanc
viru
occur
induct
nasal
serum
antibodi
indic
differ
mechan
viral
clearanc
inflammatori
respons
produc
initi
infect
hrv
appear
respons
clearanc
viru
although
inflammatori
respons
correl
symptom
asymptomat
individu
littl
inflammatori
respons
effici
clear
hrv
infect
mechan
hrv
clearanc
occur
like
involv
cellular
immun
respons
cell
recogn
heterolog
hrv
antigen
repres
memori
cell
person
prior
hrv
infect
kennedi
et
al
steink
et
al
cell
function
immun
surveil
abl
produc
rapid
adapt
immun
respons
hrv
worldwid
distribut
circul
throughout
year
temper
climat
peak
viral
activ
seen
late
summer
fall
well
late
spring
pitkaranta
hayden
although
hrv
activ
rel
low
summer
month
remain
common
caus
common
cold
throughout
year
multipl
serotyp
circul
simultan
geograph
area
clear
pattern
reappear
note
household
school
common
place
spread
hrv
infect
hrv
affect
person
age
highest
incid
document
young
children
incid
hrv
infect
children
first
year
life
note
infect
per
year
older
studi
use
cell
cultur
viral
detect
brownle
turner
recent
winther
et
al
report
averag
incid
six
picornaviru
infect
per
year
cohort
children
age
month
year
cold
remain
common
among
work
adult
averag
two
per
year
hrv
account
ill
appear
declin
frequenc
toward
middl
age
gwaltney
et
al
although
incid
acut
respiratori
tract
infect
declin
age
hrv
infect
problem
older
adult
studi
communitydwel
older
adult
hrv
identifi
ill
report
elderli
person
follow
two
winter
unit
kingdom
nicholson
et
al
addit
hrv
describ
caus
infect
older
adult
day
care
longterm
care
facil
hospit
acut
respiratori
tract
ill
asymptomat
hrv
infect
recogn
era
diagnosi
viral
cultur
widespread
use
revers
transcript
polymeras
chain
reaction
rtpcr
detect
recent
studi
demonstr
high
incid
asymptomat
infect
approxim
asymptomat
subject
sampl
posit
hrv
approxim
hrv
infect
detect
rtpcr
asymptomat
brownle
turner
find
make
assess
casualti
hrv
ill
epidemiolog
studi
challeng
without
use
control
subject
frequent
clinic
syndrom
ascrib
hrv
common
cold
aggrav
usual
selflimit
ill
sir
william
osler
character
ill
particularli
well
principl
practic
medicin
publish
patient
feel
indispos
perhap
chilli
slight
headach
sneez
frequent
first
mucou
membran
nose
swollen
stuf
patient
breath
mouth
thin
clear
irrit
secret
flow
make
edg
nostril
sore
usual
within
hour
nasal
secret
becom
turbid
profus
gradual
within
day
symptom
resolv
gwaltney
et
al
studi
gwaltney
et
al
detail
symptom
time
cours
typic
hrv
upper
respiratori
infect
uri
rhinorrhea
sneez
common
complaint
first
day
scratchi
mild
sore
throat
headach
also
common
first
day
ill
fever
uncommon
although
patient
complain
feverish
chilli
sensat
lower
respiratori
tract
symptom
hoars
cough
less
common
occur
onefourth
onethird
case
although
present
symptom
tend
linger
throughout
ill
compar
viral
respiratori
ill
significantli
sneez
occur
hrv
infect
mean
length
ill
day
rang
day
respiratori
viral
infect
felt
common
predispos
factor
acut
otiti
media
aom
middl
ear
pressur
shown
abnorm
individu
either
experiment
induc
natur
hrv
infect
mcbride
et
al
abnorm
gradual
abat
period
howev
swell
obstruct
eustachian
tube
may
lead
develop
aom
number
studi
indic
direct
viral
infect
middl
ear
fluid
possibl
hrv
detect
viral
cultur
pcr
middl
ear
fluid
infect
individu
thu
aom
may
due
viru
secondari
bacteri
infect
coinfect
greenberg
primari
viral
rhinosinus
appear
common
phenomenon
uncompl
natur
infect
hrv
sinu
abnorm
observ
comput
tomographi
ct
scan
adult
cold
gwaltney
et
al
commonli
affect
maxillari
ethmoid
sinus
though
sphenoid
frontal
sinus
could
also
affect
hrv
often
detect
cultur
rtpcr
sinu
brush
aspir
patient
viral
rhinosinus
though
pathogenesi
remain
incomplet
defin
pressur
creat
nose
blow
sneez
cough
felt
import
factor
propel
hrv
sinus
greenberg
importantli
patient
abnorm
found
ct
scan
resolv
within
week
without
antibiot
treatment
hrv
replic
effici
c
mani
year
infect
lower
respiratori
tract
higher
bodi
temperatur
felt
unlik
recent
studi
establish
hrv
replic
lower
airway
natur
experiment
infect
experiment
infect
hrv
inocul
upper
respiratori
tract
hrv
detect
situ
hybrid
bronchial
biopsi
peak
infect
week
later
papdopoulo
et
al
consist
observ
hrv
infect
link
bronchiol
exacerb
asthma
chronic
obstruct
pulmonari
diseas
copd
rare
pneumonia
hrv
import
trigger
asthma
exacerb
children
adult
gern
buss
peak
asthma
exacerb
fall
coincid
increas
hrv
activ
well
start
school
year
season
allergen
exposur
use
rtpcr
addit
standard
test
johnson
et
al
demonstr
asthma
exacerb
children
age
year
associ
viral
infect
hrv
account
approxim
twothird
addit
epidemiolog
link
hrv
asthma
hrv
human
challeng
model
provid
insight
mechan
hrv
infect
may
worsen
asthma
greenberg
papdopoulo
et
al
intranas
inhal
inocul
hrv
induc
bronchoconstrict
methacholin
challeng
subject
mild
moder
asthma
gern
buss
host
immun
respons
infect
induc
proinflammatori
mediat
lead
cascad
inflamm
activ
neural
pathway
enhanc
airway
hyperrespons
obstruct
figur
addit
asthma
hrv
associ
acut
exacerb
copd
greenberg
longitudin
studi
figur
mechan
inflamm
asthma
exacerb
trigger
human
rhinoviru
hrv
infect
host
immun
respons
infect
induc
proinflammatori
mediat
lead
cascad
inflamm
trigger
airway
hyperrespons
obstruct
respiratori
ill
hrv
commonli
identifi
pathogen
patient
moder
sever
copd
viral
infect
frequent
lead
emerg
room
visit
hospit
role
hrv
caus
bronchiti
pneumonia
immunocompet
person
unclear
number
studi
use
either
cultur
rtpcr
detect
hrv
upper
airway
small
percentag
young
children
hospit
bronchiol
pneumonia
brownle
turner
hrv
detect
children
year
age
hospit
bronchiol
sole
pathogen
similarli
children
hospit
pneumonia
hrv
found
secret
half
evid
simultan
bacteri
infect
may
associ
hrv
type
lower
respiratori
tract
diseas
frequenc
hrv
gener
popul
make
assess
causal
difficult
evid
lower
respiratori
tract
infect
hrv
immunocompromis
patient
convinc
greenberg
studi
hospit
immunocompromis
patient
develop
fatal
pneumonia
six
seven
total
case
hrv
isol
bronchiolar
lavag
fluid
endotrach
aspir
persist
hrv
lower
respiratori
tract
lung
transplant
patient
also
document
brownle
turner
ison
et
al
although
symptom
associ
common
cold
syndrom
often
attribut
hrv
diseas
clinic
find
rhinoviru
infect
indistinguish
viral
pathogen
specif
microbiolog
diagnosi
often
made
detect
hrv
cultur
molecular
assay
rare
use
immunofluoresc
serotypespecif
antibodi
assay
varieti
sampl
type
upper
airway
use
confirm
infect
includ
nasal
wash
nasopharyng
swab
combin
nose
throat
swab
though
studi
convincingli
report
lower
respiratori
tract
diseas
viru
detect
sputum
bronchoalveolar
lavag
sampl
immunocompromis
host
ison
et
al
papadopoulo
et
al
patient
time
collect
also
play
role
viru
detect
highest
concentr
viru
typic
detect
nasal
fluid
first
day
symptom
also
peak
turner
tradit
viral
cultur
use
identifi
hrv
infect
viral
isol
accomplish
inocul
viru
human
embryon
fibroblast
cell
incub
c
demonstr
cytopath
effect
cell
monolay
clinic
practic
howev
prove
timeconsum
method
diagnosi
requir
sever
day
viru
isol
yield
result
usual
acut
phase
infect
consequ
microbiolog
confirm
rare
sought
use
cultur
method
contrast
advent
new
molecular
techniqu
led
better
understand
burden
diseas
associ
hrv
infect
studi
demonstr
increas
yield
threeto
fivefold
compar
standard
viru
cultur
pitkaranta
hayden
necessarili
wide
use
practic
rtpcr
becom
standard
diagnost
tool
proven
effici
sensit
specif
detect
rhinovirus
singletarget
hrv
rtpcr
assay
use
primer
probe
conserv
region
hrv
genom
abl
detect
serotyp
pitkaranta
hayden
turner
howev
hrv
rtpcr
assay
current
avail
commerci
part
multiplex
realtim
pcr
platform
respiratori
virus
filmarray
respiratori
panel
biofir
utah
result
loss
sensit
specif
sinc
assay
unabl
distinguish
hrv
enterovirus
howev
one
potenti
benefit
use
rtpcr
practic
abil
identifi
lowlevel
viremia
asymptomat
shed
may
import
infect
control
purpos
hospit
ward
immunocompromis
patient
rhinoviru
antigen
detect
use
elisa
assay
attempt
requir
serotypespecif
antibodi
therefor
use
research
set
singl
immunoassay
develop
util
antibodi
conserv
protein
proteas
rhinoviru
unfortun
insensit
diagnost
use
turner
similarli
detect
serotypespecif
neutral
antibodi
use
diagnos
natur
hrv
infect
famili
cohort
experiment
viru
challeng
studi
impract
clinic
use
treatment
hrv
infect
support
use
overthecount
therapi
may
reduc
symptom
common
cold
syndrom
specif
hrv
infect
remedi
includ
antihistamin
nonsteroid
antiinflammatori
drug
may
allevi
symptom
without
shorten
durat
viral
shed
also
associ
sedat
therapi
report
decreas
symptom
decongest
salin
nasal
spray
expector
zinc
sulfat
lozeng
highdos
vitamin
c
shown
signific
benefit
random
control
trial
turner
current
antivir
drug
approv
clinic
use
hrv
infect
although
agent
advanc
clinic
trial
shown
modest
result
decreas
either
symptom
sever
viral
activ
leukocyt
interferon
first
agent
test
activ
rhinoviru
infect
demonstr
efficaci
prevent
infect
treatment
howev
develop
leukocyt
interferon
prophylaxi
imped
prohibit
high
cost
associ
nasal
toxic
turner
convers
monoclon
antibodi
blockad
receptor
site
cellular
attach
major
hrva
hrvb
serotyp
also
studi
demonstr
reduct
sever
symptom
viral
shed
fail
prevent
infect
rhinoviru
challeng
model
greenberg
moreov
discoveri
hrvc
virus
util
differ
cellular
receptor
interest
approach
wane
hrv
proteas
cleav
rhinoviru
genom
individu
structur
enzymat
compon
import
viral
replic
turner
highli
conserv
among
rhinoviru
serotyp
consequ
target
antivir
therapi
ruprintrivir
proteas
inhibitor
experiment
trial
prevent
rhinoviru
infect
clinic
trial
modestli
reduc
ill
sever
treatment
initi
within
day
infect
patick
et
al
final
hydrophob
pocket
form
canyon
region
capsid
facilit
attach
receptor
host
cell
also
target
drug
develop
capsidbind
agent
bind
hydrophob
pocket
prevent
viral
attach
cellular
receptor
therefor
viral
replic
pleconaril
capsidbind
agent
demonstr
antivir
activ
enterovirus
two
larg
random
doubleblind
placebocontrol
trial
patient
common
cold
symptom
treat
pleconaril
versu
placebo
within
h
symptom
onset
greenberg
compar
placebo
pleconaril
treatment
result
reduc
ill
durat
day
overal
decreas
sever
symptom
howev
found
induc
cytochrom
enzym
therefor
approv
food
drug
administr
due
potenti
sever
drugdrug
interact
greenberg
new
formul
agent
current
consid
clinic
trial
effort
develop
effect
vaccin
hrv
infect
unsuccess
date
strategi
prevent
hrv
infect
focus
primarili
interrupt
transmiss
sinc
transmiss
occur
direct
contact
standard
precaut
includ
appropri
handwash
practic
like
effect
prevent
tool
highrisk
patient
patient
undergon
recent
stem
cell
transplant
stringent
infect
control
practic
includ
screen
symptomat
patient
earli
implement
droplet
contact
precaut
restrict
visitor
upper
respiratori
tract
symptom
shown
reduc
rate
nosocomi
infect
ison
et
al
number
handwash
agent
assess
potenti
virucid
activ
hand
sanit
contain
ethanol
treatment
acid
compound
turner
none
demonstr
efficaci
prevent
infect
like
effect
use
soap
water
shortli
discoveri
rhinovirus
serum
serotypespecif
neutral
antibodi
nasal
hrvbind
immunoglobulin
iga
shown
protect
infect
effort
develop
hrv
vaccin
soon
follow
initi
clinic
trial
human
involv
use
formalininactiv
singl
serotyp
hrv
vaccin
result
trial
demonstr
signific
reduct
rate
symptomat
cold
glanvil
johnston
howev
discoveri
hrv
antigen
divers
result
differ
serotyp
isol
approach
abandon
favor
multival
vaccin
incorpor
serotyp
unfortun
fail
demonstr
signific
crossprotect
among
hrv
serotyp
consequ
hrv
vaccin
research
larg
abandon
year
recent
advanc
develop
mous
modelfor
hrv
infect
permit
explor
altern
approach
immun
includ
induct
cellmedi
immun
one
recent
report
recombin
protein
precursor
appear
highli
conserv
hrva
hrvb
serotyp
use
immunogen
mice
shown
induc
crossserotyp
cell
recruit
activ
well
neutral
antibodi
product
result
acceler
clearanc
viru
vivo
mclean
approach
suggest
crossserotyp
protect
possibl
unlik
singl
immunogen
gener
protect
hrv
serotyp
may
use
candid
broadli
protect
subunit
vaccin
hrv
infect
person
age
infect
children
occur
two
seven
time
year
continu
life
result
two
five
symptomat
ill
per
year
adult
ill
mild
selflimit
atrisk
popul
hrv
infect
may
result
sever
ill
consequ
though
innocu
refer
common
cold
hrv
infect
constitut
signific
burden
associ
health
care
econom
cost
studi
need
understand
pathogenesi
diseas
adapt
immun
respons
associ
hrv
infect
may
also
provid
new
target
antivir
agent
broadli
crossprotect
vaccin
see
also
influenza
pneumonia
respiratori
infect
acut
respiratori
syncyti
viru
viral
infect
overview
focu
prevent
transmiss
